Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.
Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous injection) as add-on to metformin for 32 weeks.
Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the efficacy, safety, pharmacokinetics, and immunogenicity of them are similar.